Surrozen Collaborates with TCGFB for Developing TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
Shots:
- Surrozen has entered into a research collaboration with TCGFB to develop antibody therapeutics targeting TGF-β for treating idiopathic pulmonary fibrosis (IPF), leveraging former’s expertise for the discovery of same
- As per the agreement, Surrozen will offer antibody discovery services for over 2yrs., with TCGFB retaining all TGF-β product-related intellectual property
- TCGFB will pay a total of $6M (plus any third-party costs) and issue a warrant for 3,380,000 shares of TCGFB common stock at $0.0001 per share, subject to vesting conditions
Ref: Surrozen | Image: Surrozen
Related News:- AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
